Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), James McCloskey(Hackensack University Medical Center), Elizabeth A. Griffiths(Roswell Park Comprehensive Cancer Center), Karen Yee(Princess Margaret Cancer Centre), Amer M. Zeidan(Yale Cancer Center), Aref Al‐Kali(Mayo Clinic in Arizona), H. Joachim Deeg(Fred Hutch Cancer Center), Prapti A. Patel(The University of Texas Southwestern Medical Center), Mitchell Sabloff(Ottawa Hospital), Mary‐Margaret Keating(Queen Elizabeth II Health Sciences Centre), Nancy Zhu(University of Alberta), Nashat Gabrail(Gabrail Cancer Center), Salman Fazal(Allegheny Health Network), Joseph Maly(Norton Healthcare), Olatoyosi Odenike(University of Chicago), Hagop Kantarjian(The University of Texas MD Anderson Cancer Center), Amy E. DeZern(Johns Hopkins University), Casey L. O’Connell(Keck Hospital of USC), Gail J. Roboz(Presbyterian Hospital), Lambert Busque(Hôpital Maisonneuve-Rosemont), Rena Buckstein(Health Sciences Centre), Harshad Amin(Boca Raton Regional Hospital), Jasleen K. Randhawa(Houston Methodist), Brian Leber(Juravinski Cancer Centre), Aditi Shastri(Montefiore Einstein Comprehensive Cancer Center), Kim‐Hien Dao(Astex Pharmaceuticals), Aram Oganesian(Astex Pharmaceuticals), Yong Hao(Astex Pharmaceuticals), Harold Keer(Astex Pharmaceuticals), Mohammad Azab(Astex Pharmaceuticals), Michael R. Savona(Vanderbilt University Medical Center)
Cited by 81
Abstract
Related Papers
No related papers found
Powered by citation graph analysis